Harvard Bioscience, Inc.

NasdaqGM:HBIO 주식 보고서

시가총액: US$123.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Harvard Bioscience 대차 대조표 상태

재무 상태 기준 확인 5/6

Harvard Bioscience 의 총 주주 지분은 $68.8M 이고 총 부채는 $35.6M, 이는 부채 대 자기자본 비율을 51.7% 로 가져옵니다. 총자산과 총부채는 각각 $133.2M 및 $64.3M 입니다.

주요 정보

51.7%

부채 비율

US$35.61m

부채

이자 보상 비율n/a
현금US$4.26m
주식US$68.81m
총 부채US$64.35m
총 자산US$133.16m

최근 재무 상태 업데이트

Recent updates

Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Dec 22
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely

Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Sep 23
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price

Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 10
Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Apr 26
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Apr 11
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt

Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M

Aug 04

Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Jun 08
Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt

Harvard Bioscience - Dressed Up And Waiting For A Suitor

Mar 15

Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Feb 16
Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Nov 04
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

Oct 01
Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

May 04
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued

These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Apr 19
These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively

Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Apr 04
Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)

Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

Mar 20
Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?

What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Mar 07
What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?

Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

Feb 17
Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain

An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Feb 02
An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued

Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Jan 15
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?

Harvard Bioscience: Wait For The Green Shoots Of Improvement

Jan 12

When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Dec 28
When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?

Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

Dec 11
Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?

At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?

Nov 26
At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?

Harvard Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

재무 상태 분석

단기부채: HBIO 의 단기 자산 ( $48.1M )이 단기 부채( $25.7M ).

장기 부채: HBIO 의 단기 자산( $48.1M )이 장기 부채( $38.7M ).


부채 대 자본 내역 및 분석

부채 수준: HBIO 의 순부채 대 자기자본 비율( 45.6% )은 높음으로 간주됩니다.

부채 감소: HBIO 의 부채 대 자기자본 비율은 지난 5년간 70.6% 에서 51.7% 로 감소했습니다.


대차 대조표


현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: 수익성이 없는 HBIO 현재의 플러스 무료 현금 흐름 수준을 유지한다면 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: HBIO 은(는) 수익성이 없지만 잉여 현금 흐름이 긍정적이고 매년 10.1 %씩 성장하기 때문에 3년 이상 충분한 현금 활주로를 보유하고 있습니다.


건강한 기업 발견하기